Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Pure Bioscience's free cash flow for the twelve months ending Jul 31, 2023 was -$3.31M. For fiscal 2023 it was -$3.31M. The highest annual figure on record is $611.00K in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Jul 31, 2023 | -$3.31M | – |
| FY2022 | Jul 31, 2022 | -$2.50M | – |
| FY2021 | Jul 31, 2021 | -$1.69M | -376.3% |
| FY2020 | Jul 31, 2020 | $611.00K | – |
| FY2019 | Jul 31, 2019 | -$3.00M | – |
| FY2018 | Jul 31, 2018 | -$3.91M | – |
| FY2017 | Jul 31, 2017 | -$4.77M | – |
| FY2016 | Jul 31, 2016 | -$5.38M | – |
| FY2015 | Jul 31, 2015 | -$6.14M | – |
| FY2014 | Jul 31, 2014 | -$6.35M | – |
| FY2013 | Jul 31, 2013 | -$3.92M | – |
| FY2012 | Jul 31, 2012 | -$5.60M | – |
| FY2011 | Jul 31, 2011 | -$6.14M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$701.00K | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$704.00K | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$967.00K | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$939.00K | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$620.00K | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$620.00K | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$629.00K | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$630.00K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$429.00K | -123.6% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$347.00K | – |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$539.00K | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$373.00K | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $1.82M | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | -$224.00K | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$657.00K | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$831.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$441.00K | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$1.07M | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$664.00K | – |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$1.10M | – |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$1.10M | – |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$1.04M | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -$1.17M | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -$1.20M | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | -$1.27M | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | -$1.12M | – |
See a number that looks wrong?